Abstract:Abstract Background/Aims There has been an increase in interest in identifying patients with high risk of fracture, due to the high mortality. In De Laet et al. (2005) meta-analysis on 60000 women and men, which analysed the effect of body mass index (BMI), bone mineral density (BMD), age and gender on risk of any fracture; low BMI is linked to significantly higher fracture risk (two-fold at BMI of 20) when compared with a BMI 25. On the same comparison, high BMI (30) reduced risk of fractures by 17% (RR 0.83). This was significant in women, but not in men. No newer large-scale study focused on the correlation between BMI and fracture risks in men. Therefore, we set out to investigate the relationship between BMI and different fractures in male patients. Methods 5388 male patients referred for DEXA scan in the North West of England between 2004 and 2019 were included in the analysis. Logistic regression is performed for age, BMI, and BMD using R-4.3.1 for Windows. Results Prior to adjusting for BMD, low BMI is a significant risk factor for femur fracture. On the other hand, low BMI is a protective factor against tibia-fibula fractures. There was no significant correlation detected in spine, rib, humerus, forearm and elbow fractures. After adjusting for BMD, higher BMI is associated with significantly higher odds of humerus, tibia-fibula and wrist fractures, but no statistically significant association with spine, ribs and femur fractures. Conclusion Our results show the correlation between BMI, adjusted for BMD, and different fracture site. Our findings corroborated with previous literature, suggesting that BMI is likely a risk factor that is dependent on BMD. Furthermore, we highlighted that higher BMI is a protective factor for some fractures whilst being a risk factor for others. It is unclear whether the difference between the fracture types are due to the mechanism of fracture or the difference in disease progression at the different fracture sites - this is a potential area for future research. Disclosure M.H. Nguyen: None. M. Bukhari: None.

What problem does this paper attempt to address?

### What problems does this paper attempt to solve? This paper explores the association between intravenous iron preparations (especially Ferric Carboxymaltose, FCM) and rheumatology, with an emphasis on hypophosphatemia osteomalacia (referred to as 6H - syndrome for short) caused by intravenous iron preparations. Specifically, the research attempts to solve the following problems: 1. **Side effects of intravenous iron preparations**: The study aims to reveal the hypophosphatemia that may be caused by intravenous iron preparations (especially Ferric Carboxymaltose) and its impact on bone health. Hypophosphatemia may lead to osteomalacia, a disease of insufficient bone mineralization, and common symptoms include bone pain, joint pain, and pseudofractures. 2. **Causes of diagnostic delay**: The study points out that doctors' unfamiliarity with the side effects of intravenous iron preparations has led to diagnostic delays. In particular, when patients develop hypophosphatemia, they fail to immediately associate intravenous iron preparations as one of the possible causes. 3. **Selection of treatment regimens**: The study explores how to adjust the treatment regimens for patients after the diagnosis of hypophosphatemia osteomalacia. For example, stop intravenous iron preparations and switch to oral iron preparations, and use drugs such as Dipyridamole to improve biochemical indicators and relieve symptoms. 4. **Clinical warnings**: The study emphasizes the importance of inquiring about intravenous iron preparations in patients' medical histories. Especially when patients present with hypophosphatemia and musculoskeletal pain, it is necessary to consider whether it is osteomalacia and conduct further examinations. ### Key findings - **Frequency of hypophosphatemia**: After intravenous injection of FCM, the incidence of hypophosphatemia is relatively high, usually 1/100 to <1%, and is mostly self - limiting and asymptomatic. However, repeated infusions may lead to persistent hypophosphatemia, which in turn may cause osteomalacia. - **Role of FGF23**: The study found that some iron preparations (such as FCM) can cause an increase in FGF23 levels, leading to an increase in urinary phosphorus excretion and thus causing hypophosphatemia. - **Effect of Dipyridamole**: Dipyridamole has the effect of inhibiting FGF23, which helps to improve the biochemical indicators and symptoms of patients with hypophosphatemia. ### Conclusions The study recommends that in patients receiving intravenous iron preparations, serum phosphorus levels should be monitored two and five weeks after infusion, and a re - evaluation should be made on whether to continue using FCM. In addition, for patients with persistent hypophosphatemia, consideration should be given to adjusting the treatment regimen. This case emphasizes the importance of inquiring about intravenous iron preparations in patients' medical histories, and that musculoskeletal pain may be a manifestation of osteomalacia and requires further investigation. Through these research results, the paper provides an important reference for clinicians to better identify and handle hypophosphatemia osteomalacia caused by intravenous iron preparations.

P076 Exploring the correlation between body mass index and fracture risk in men

Body mass index as a predictor of fracture risk: A meta-analysis

Relationship Between Body Mass Index and Fracture Risk Is Mediated by Bone Mineral Density

A study on bone mass density using dual energy X-ray absorptiometry: Does high body mass index have protective effect on bone density in obese patients?

Association of fall risk, bone mineral density, muscle strength, and body fat content in patients with osteoporotic fractures

Risk of Subsequent Fractures and Mortality in Elderly Women and Men with Fragility Fractures with and without Osteoporotic Bone Density: The Dubbo Osteoporosis Epidemiology Study

OA37 Regional variations in adiposity is a strong predictor of fragility fractures in a large cohort: a cross sectional study

Partial body fat percentage as a predictor of fragility fractures in a large cohort: a cross-sectional study

Associations of Body Composition Trajectories with Bone Mineral Density, Muscle Function, Falls and Fractures in Older Men: The Concord Health and Ageing in Men Project.

The Correlation Between Hip BMD and Hip Fracture

General and abdominal obesity operate differently as influencing factors of fracture risk in old adults

Distribution of Fracture Sites in Postmenopausal Overweight and Obese Women: The FRISBEE Study

Impact of body mass index on fracture severity, clinical, radiological and functional outcome in distal radius fractures: a retrospective observational study after surgical treatment

Effect of abdominal tissue thickness on trabecular bone score and fracture risk in adults with diabetes: the Manitoba BMD registry

Fat Mass Has Negative Effects on Bone, Especially in Men: A Cross-sectional Analysis of NHANES 2011-2018

Optimal body mass index for protecting middle-aged and elderly patients with fatty liver from future fractures

The role of hypertension in bone mineral density among males older than 50 years and postmenopausal females: evidence from the US National Health and Nutrition Examination Survey, 2005–2010

Fracture Risk Associated with Different Numbers and Combinations of Lumbar Vertebrae: The Manitoba BMD Registry

Association of obesity with osteoporotic fracture risk in individuals with bone metabolism-related conditions: a cross sectional analysis

The relationship of body composition with bone mineral density and 10-year probability of hip fracture in postmenopausal women

Discrimination of Vertebral Fragility Fracture with Lumbar Spine Bone Mineral Density Measured by Quantitative Computed Tomography